[ad_1] Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024…
[ad_1] Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. Dado Ruvic | Reuters Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen jumped more than 80% Thursday, putting it on track for its…
[ad_1] Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world’s biggest cancer research conference in Chicago, starting Thursday. Investors have already caught a glimpse of the topics that will be discussed but many are eager to hear the details behind the abstracts, and no doubt…
